| Year |
Citation |
Score |
| 2019 |
DONG S, MOWERY CT, HEROLD KC, GITELMAN SE, ESENSTEN JH, LIU W, LARES AP, LEINBACH AS, LEE MR, NGUYEN VQ, PUTNAM AL, YE J, TANG Q, BLUESTONE J. 253-LB: Effect of Combined Low Dose IL-2 plus Polyclonal Tregs in Type 1 Diabetes Patients Diabetes. 68: 253-LB. DOI: 10.2337/Db19-253-Lb |
0.421 |
|
| 2019 |
Okada K, Nguyen A, Watchmaker P, Xu J, Ramsdell F, Esensten JH, Butterfield LH, Okada H. Development of a large-scale H3.3K27M-specific TCR-transduced T cell manufacturing method for adoptive cell therapy in HLA-A2+ patients with diffuse midline glioma Cytotherapy. 21. DOI: 10.1016/J.Jcyt.2019.03.367 |
0.493 |
|
| 2018 |
Esensten JH, Muller YD, Bluestone JA, Tang Q. Regulatory T cell therapy for autoimmune and autoinflammatory diseases: the next frontier. The Journal of Allergy and Clinical Immunology. PMID 30367909 DOI: 10.1016/J.Jaci.2018.10.015 |
0.41 |
|
| 2018 |
Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, Hiatt J, Saco J, Krystofinski P, Li H, Tobin V, Nguyen DN, Lee MR, Putnam AL, Ferris AL, ... ... Esensten JH, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. PMID 29995861 DOI: 10.1038/S41586-018-0326-5 |
0.449 |
|
| 2018 |
Shy BR, Whitman J, Putnam AL, Lares A, Tang Q, Esensten JH. Developing a database to track critical parameters for clinical regulatory T cell manufacturing Cytotherapy. 20. DOI: 10.1016/J.Jcyt.2018.02.317 |
0.416 |
|
| 2016 |
Esensten JH, Bluestone JA, Lim WA. Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials. Annual Review of Pathology. PMID 27959633 DOI: 10.1146/Annurev-Pathol-052016-100304 |
0.463 |
|
| 2016 |
Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 Costimulation: From Mechanism to Therapy. Immunity. 44: 973-88. PMID 27192564 DOI: 10.1016/J.Immuni.2016.04.020 |
0.425 |
|
| 2013 |
MartÃnez-Llordella M, Esensten JH, Bailey-Bucktrout SL, Lipsky RH, Marini A, Chen J, Mughal M, Mattson MP, Taub DD, Bluestone JA. CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response. The Journal of Experimental Medicine. 210: 1603-19. PMID 23878307 DOI: 10.1084/Jem.20122387 |
0.489 |
|
| 2013 |
de Kouchkovsky D, Esensten JH, Rosenthal WL, Morar MM, Bluestone JA, Jeker LT. microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. Journal of Immunology (Baltimore, Md. : 1950). 191: 1594-605. PMID 23858035 DOI: 10.4049/Jimmunol.1203567 |
0.326 |
|
| 2011 |
Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunological Reviews. 241: 180-205. PMID 21488898 DOI: 10.1111/J.1600-065X.2011.01011.X |
0.497 |
|
| 2011 |
McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, Hoffmüller U, Baron U, Olek S, Bluestone JA, Brusko TM. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. Journal of Immunology (Baltimore, Md. : 1950). 186: 3918-26. PMID 21368230 DOI: 10.4049/Jimmunol.1003099 |
0.43 |
|
| 2010 |
McClymont S, Putnam A, Lee M, Esensten J, Liu W, Olek S, Baron U, Hoffmuller U, Bluestone J, Brusko T. Plasticity of Human Regulatory T Cells - Characterization of IFN-γ-Producing Cells Clinical Immunology. 135: S5-S6. DOI: 10.1016/J.Clim.2010.03.023 |
0.462 |
|
| 2009 |
Esensten JH, Wofsy D, Bluestone JA. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nature Reviews. Rheumatology. 5: 560-5. PMID 19798031 DOI: 10.1038/Nrrheum.2009.183 |
0.44 |
|
| 2009 |
Esensten JH, Lee MR, Glimcher LH, Bluestone JA. T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. Journal of Immunology (Baltimore, Md. : 1950). 183: 75-82. PMID 19535634 DOI: 10.4049/Jimmunol.0804154 |
0.477 |
|
| Show low-probability matches. |